177 results about "Cellular senescence" patented technology

The invention provides a construction method of a predictive cell senescence model, a method for predicting the senescence state of a tissue sample based on the senescence model, a method for screening potential therapeutic drugs, equipment, a medium and a program product, and relates to the field of intelligent medical treatment. The model construction method comprises the following steps: acquiring a training set sample expression profile data set; identifying a key senescence gene set from the data set by using a feature selection algorithm; inputting the key senescence gene set into a machine learning model to fit a prediction model, and determining an optimal hyper-parameter to obtain a cell senescence model containing the weight of a single gene in the key senescence gene set; the cell senescence model is a senescence score obtained by calculating the sum of the product of the expression quantity of a single gene and the regression coefficient thereof. The cell senescence model, namely PreCSenM, is constructed by integrating a plurality of senescence characteristic gene sets and a gene scoring algorithm, the accuracy in CS evaluation is superior to that of 10 existing methods, and the application of CS from biological research to clinical scenes is also realized.

The invention belongs to the technical field of biomedicine, and discloses application of histone lactic acid modification as a target spot in preparation of a medicine for preventing or treating chronic obstructive pulmonary diseases, in particular to lactic acid modification on 18th lysine residues of histone 3, and the expression level of ATM protein in airway epithelial cells is up-regulated through the histone lactic acid modification, so that the chronic obstructive pulmonary diseases can be prevented or treated. The expression of cell senescence key genes is promoted, so that the senescence phenotype of airway epithelial cells is aggravated, and the airway epithelial cells participate in the disease process of mediating the chronic obstructive pulmonary disease. The discovery provides a new therapeutic target for the chronic obstructive pulmonary disease.

The invention belongs to the technical field of biology, and particularly relates to a genetically modified mesenchymal stem cell as well as a preparation method and application thereof. The invention relates to a gene modified mesenchymal stem cell, the gene modified mesenchymal stem cell is a mesenchymal stem cell of an over-expression SIRT6 gene, and the acquisition number of the SIRT6 on NCBI (National Center of Biotechnology Information) is NM001193285. The invention finds that SIRT6 is helpful for delaying the cell senescence process and obviously improving the anti-senescence capability of cells by regulating senescence-related genes and proteins.

The invention provides application of scEMC10 in treatment and diagnosis of cerebral vascular endothelial cell senescence, and relates to the technical field of biomedicine. The research of the inventor finds that brain microvascular endothelial cell senescence is caused by the lack of scEMC10; after the brain microvascular endothelial cells are treated by scEMC10, beta-galactosidase, SASP and classic senescence markers related to senescence can be down-regulated; after scEmc10 is supplemented to old mice and Alzheimer's disease 5XFAD model mice, the motion coordination ability and the spatial cognitive ability of the mice can be obviously improved, the relative content of a marker phosphorylated alpha-synuclein of the Parkinson's disease of the old mice can be obviously reduced, and the content of tyrosine hydroxylase phosphorylated active forms can be increased. Therefore, the scEMC10 can be used for treating brain microvascular endothelial cell senescence, improving Alzheimer's disease and Parkinson's disease and detecting brain microvascular endothelial cell senescence as a marker.

The invention discloses a construction method and application of a cell senescence model, and belongs to the technical field of biology, firstly, cells are cultured in an embryonic-stage animal serum complete medium to a logarithmic phase for passage, then the cells are inoculated with an embryonic-stage animal serum complete medium, a newborn-stage animal serum complete medium or an adult-stage animal serum complete medium respectively, and the cell senescence model is obtained. The method comprises the following steps of: culturing and observing the cell state, and determining cell senescence by SA-beta-gal staining and detecting the transcriptional level of senescence-related genes when the cells grow slowly and become large and flat in comparison with an animal serum group in an embryonic period, so as to prove that the cell senescence model is successfully constructed. The cell senescence model is simple and convenient to operate, and the senescence induction process is simple, stable and rapid; the cell senescence model induced by newborn animal serum and adult animal serum simulates the senescence process of organisms of different age groups in vitro, and breaks through the limitation that cell senescence phenotypes are generated by oxidative stress treatment.

The invention discloses a composition for delaying cell senescence, and the composition for delaying cell senescence comprises fisetin, urolithin A and ergothioneine, or consists of fisetin, urolithin A and ergothioneine. The invention also discloses an application of the composition for delaying cell aging in preparation of a product for delaying skin fibroblast aging, and an anti-aging preparation containing the composition. According to the composition for delaying cell aging, fisetin, urolithin A and ergothioneine contained in the composition can generate a synergistic effect, aging of skin fibroblasts can be remarkably delayed, and healing and repairing of skin are promoted.

The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a preparation method therefor. The compound represented by Chemical Formula 1, according to the present invention, has an excellent effect of increasing the expression level of the klotho gene which is a gene associated with aging, and thus can be useful for a pharmaceutical composition, cosmetic composition or food composition for preventing skin aging, inhibiting cellular senescence or preventing, treating alleviating a vascular aging-induced disease or a renal disease.

The invention relates to application of thyroid hormone T3 in preparation of a medicine for delaying or treating intervertebral disc degeneration, and the thyroid hormone T3 can inhibit glycolysis capability of degeneration nucleus pulposus cells and reduce intervertebral disc lactic acid accumulation, so that nucleus pulposus cell senescence and apoptosis are relieved, and intervertebral disc degeneration is delayed or treated. Compared with the prior art, the technology for delaying or treating intervertebral disc degeneration by applying the thyroid hormone T3 provides new application of the thyroid hormone T3, the application value of the thyroid hormone T3 is greatly improved, the application range of the thyroid hormone T3 is expanded, the new field of application of the thyroid hormone T3 is expanded, and the thyroid hormone T3 has wide application prospects and commercial value.

Provided herein are methods for mechanically conditioning cells to improve their proliferative function and multipotency, as well as protect them from advancing senescence. In the methods, brachial loading alone is first used to improve the efficiency of culture expansion. Once a sufficient population of healthy cells are generated, pharmacological agents are added as a cotreatment to drive differentiation into a desired phenotype. The conditioned cells may then be used to prepare compositions for administration to a patient to treat a disease.

The present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases, comprising a nuclear receptor subfamily 2 group F member 1 (NR2F1) inhibitor. The NR2F1 inhibitor of the present invention rejuvenates retinal cells by inhibiting the expression of the NR2F1 gene or the activity of the NR2F1 protein, and thus has the effects of reducing cellular senescence of retinal pigment epithelial cells and restoring visual function.

The invention relates to the field of cell culture, in particular to a culture composition of stem cells and a culture method. The culture composition comprises NAD (Nicotinamide Adenine Dinucleotide) or a precursor thereof, flavonoid and coenzyme, and can be used for improving the proliferation capacity of stem cells and inhibiting the aging of the stem cells.

Provided is a rejuvenating agent that restores cell function, suppresses senescence-associated secretory phenotypes (SASP), extends telomeres, and restores cell division capability.　This rejuvenation agent is for use by administration to subjects having cells and contains microparticles derived from dental-pulp-derived stem cells. The present invention also provides a rejuvenation method.

The invention mainly relates to composite hydrogel of a targeted cartilage end plate as well as a preparation method and application of the composite hydrogel, and belongs to the technical field of biological medicines. The composite hydrogel of the targeting cartilage end plate comprises a cartilage targeting peptide modified drug-loaded exosome, calcium carbonate, chitosan and water, and the cartilage targeting peptide modified drug-loaded exosome comprises an exosome, a cartilage targeting peptide and salvianolic acid A. The composite hydrogel of the targeting cartilage end plate is prepared by the following steps: encapsulating salvianolic acid A by exosome derived from human mesenchymal stem cells, modifying by cartilage targeting peptide to obtain drug-loaded exosome modified by the cartilage targeting peptide, and mixing the drug-loaded exosome with calcium carbonate, chitosan and water. The compound can be used for accurately targeting cartilage endplate cells (CEPCs), remarkably relieving the inflammation of the CEPCs, changing the secretion phenotype of the CEPCs, delaying the senescence of nucleus pulposus cells (NPCs), relieving the inflammation of the NPCs and effectively treating intervertebral disc diseases.

The invention discloses a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia and application, and relates to the technical field of biomedicine. The invention provides a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia. The combined pharmaceutical composition comprises vincristine and cytarabine or pharmaceutically acceptable salts and solvates of the vincristine and the cytarabine. According to the vincristine and cytarabine combined pharmaceutical composition, the apoptosis level of acute myelogenous leukemia cells can be remarkably improved, and compared with single-drug treatment, the vincristine and cytarabine combined pharmaceutical composition has higher anti-tumor efficacy; vincristine interferes or blocks a cell senescence state induced by cytarabine through a microtubule destruction effect, so that the problem of drug insensitivity caused by cell senescence is solved, and drug resistance caused by cell senescence is effectively reversed.

The present invention provides a method for cell anti-aging, in which a constructed cell aging model is first treated with mesenchymal stem cells for 12-48 hours, and then metformin is added for 12-48 hours. This combined therapy can significantly enhance the expression level of glutathione peroxidase 7 (GPx7) in aging IMR-90 cells, thereby greatly reversing the aging state of IMR-90 cells.

The invention discloses a method for screening potential treatment targets of acrolein-induced retinal injury, and relates to the field of acrolein toxicity prediction. According to the method disclosed by the invention, a retinal injury related differential expression gene and an acrolein related target spot are obtained, an intersection is taken, protein interaction relationship network analysis is carried out, and a potential mechanism of acrolein-induced retinal injury is predicted. GO functional clustering analysis results show that acrolein is mainly subjected to biological processes such as apoptosis signal channel regulation and epithelial cell development, and KEGG key signal channel enrichment analysis results show that acrolein may induce retinal injury through IL-17 signal channels, human cytomegalovirus infection and cell senescence cell signal channels. The predicted key genes comprise CXCR4, EDN1, ITGA6 and PECAM1, and a new target is provided for subsequent prevention and treatment of acrolein-induced retinal injury.

This invention relates to the field of biotechnology, specifically disclosing an aging biomarker capable of marking cellular senescence and its applications. The purpose of this invention is to provide a novel biomarker for assessing cellular senescence and its applications, aiming to address the problem of the lack of highly specific biomarkers for the senescence status of immune cells in tumor tissues in existing technologies, particularly the technical bottleneck of accurately assessing the degree of immune cell senescence in the complex tumor microenvironment.

The present invention describes for the first time a method for preventing and / or reversing the phenomenon of premature senescence of skin cells and complex chronic wounds, characterized in that an effective amount of the growth hormone secretagogue peptide GHRP6 is applied. Also object of the present invention is a method for treating cases of complex chronic wounds that have developed primary or secondary refractoriness caused by the development of a cellular senescence process, transforming them from refractory wounds to responsive wounds in the presence of proliferative agents with which they unexpectedly manage to reverse and restart the healing process. Complex chronic wounds include cases of diabetic foot ulcers, venous ulcers, pressure ulcers, radiation ulcers, and other types of chronic wounds that are characterized by refractoriness to all types of treatment. These cases currently have no effective treatments.

The invention belongs to the technical field of polypeptides, and particularly relates to a novel synthetic polypeptide and a synthetic method and application thereof. The skin as the largest organ of the human body can visually reflect the aging level of the whole body. Skin senescence can be divided into endogenous senescence and exogenous senescence, the main manifestation of the cellular level is the senescence of fibroblasts in a corium layer, research shows that reactive oxygen species (ROS) is an important factor for promoting cell senescence, and the cell anti-senescence effect can be achieved by reducing the generation of ROS in cells. Melanin is a heterogeneous polyphenol-like polymer which is synthesized in melanin bodies and has a complex structure, the amount and distribution of the melanin not only determine the depth of the skin color, but also cause hyperpigmentation diseases due to metabolic disorder. In recent years, research finds that the polypeptide has excellent performance in skin care due to good biocompatibility and relatively strong biological activity. The polypeptide can rapidly permeate the skin through a specific receptor and activate the regeneration and repair functions of skin cells, so that the whitening and anti-aging effects are achieved. In addition, the action mechanism of the polypeptide is relatively mild, and the polypeptide is suitable for various skin types, especially sensitive skin. At present, although multiple polypeptide products exist in the market, most of the polypeptide products integrate a single function, and comprehensive products with double effects of whitening and anti-aging are lacked. Therefore, a polypeptide product with whitening and anti-aging effects is developed, the requirements of consumers can be better met, and the polypeptide product has important market value and application prospect.

The present invention belongs to the field of biomedical technologies and discloses the use of arylsulfatase K in the preparation of drugs for preventing, delaying or treating chronic obstructive pulmonary disease. The present invention has for the first time discovered the role of ARSK (arylsulfatase K) in inhibiting mitophagy and delaying the senescence of airway epithelial cells, and further determined the key role of ARSK in the occurrence and development of COPD, which can provide a new target for the prevention and treatment of COPD. The present invention has determined that ARSK can slow down the process of lung senescence by alleviating the process of mitophagy, inhibiting the senescence of airway epithelial cells, thereby providing a new treatment strategy for COPD.

The invention discloses a lactobacillus paragasseri strain capable of converting anthocyanin to generate various active metabolites, inhibiting NF-kappa B and cGAS-STING signals and enhancing inflammatory response relieving, and belongs to the technical field of microorganisms and the technical field of medicines. The lactobacillus paragasseri CCFM1499 provided by the invention can be used for converting anthocyanin into various active substances such as homovanillic acid, cyanidin, 3 ', 4'-dihydroxyphenylacetic acid and the like; fermentation supernate obtained by fermenting anthocyanin through the lactobacillus paragasseri CCFM1499 has the following effects: (1) the capability of reducing inflammatory factors of cells is achieved; (2) the cell senescence phenotypic capability is relieved; (3) the cGAS-STING signal channel capability is inhibited; and (4) inhibiting the NF-kappa B signal path capability. The lactobacillus paragasseri CCFM1499 fermented anthocyanin provided by the invention can be used for preparing a product for relieving inflammatory response, and has a huge application prospect.

The present invention relates to a composition comprising a phospholipid of marine origin, the present invention relates to a composition for improving at least one aging marker selected from the group consisting of genomic instability, telomere shortening, epigenetic alterations, loss of protein homeostasis, dysnutrition induction, mitochondrial dysfunction, cellular senescence, stem cell depletion, and dysnutrition induction and intercellular communication.

The MYC and NMYC transcription factors (TFs) play a key role in cell proliferation and are overexpressed in most cancer cells. However, in normal cells their overexpression triggers safeguard mechanisms promoting cell death and cellular senescence, which are bypassed in cancer cells. Here, the inventors reveal that in normal cells MYC binds to the Inositol 1,4,5-Trisphosphate Receptor type 1 (ITPR1) gene and upregulates its expression, triggering an ER-mitochondria calcium (Ca2+) transfer, which is involved in MYC-induced cell death and senescence. Supporting a tumor suppressive role of MYC / ITPR1 axis, ITPR1 expression is generally decreased in cancer and reactivation of this pathway induces cancer cell death. Nevertheless, some cancer cells, generally expressing high levels of MYCN and / or MYC, also express high level of ITPR1, which correlates with high expression of BCL2, encoding an inhibitor of ITPR1. Strikingly, in high-risk MYCN-amplified neuroblastoma, ITPR1 expression is controlled by NMYC and its level correlates with worse patient survival. In these cells, blocking the interaction between BCL2 and ITPR1, via an BCL2-BH4 domain inhibitor induces mitochondrial Ca2+ accumulation and cell death, and decreases tumor size. Thus, the present invention relates to a method for treating MYChigh cancer, and in particular NMYC--amplified neuroblastoma in a subject by administering an BCL2-BH4 domain inhibitor.

The invention discloses an application of miR-26a-5p in preparation of a product for preventing, repairing or treating cell aging. According to the invention, miR-26a-5p is applied to preparation of products for preventing and treating cell aging for the first time, a brand new molecular intervention strategy is provided for cell aging resistance, and the problem of lack of targeted molecular targeting schemes in the prior art is effectively overcome. The miR-26a-5p can be used for remarkably regulating and controlling the expression of cell cycle key factors CDK1, p21, Ki67 and Lamin B1, so that the proliferation state and the aging process of cells are accurately intervened.

This invention discloses the application of lipoic acid analog formulations in the preparation of anti-cardiomyocyte senescence products. The lipoic acid analog DMAE-LA is N-(2-(dimethylamino)ethyl)-5-(1,2-dithiopentane-3-yl)pentanamide, with a concentration of 2-25 μM. DMAE-LA pretreatment effectively reduces intracellular ROS, improves mitochondrial function, inhibits the overexpression of p21 and HMGB1, and restores Lamin B1 levels, thereby alleviating the senescent manifestations of cardiomyocytes. DMAE-LA reduces H₂S oxidative depletion by inhibiting ROS generation and may promote H₂S synthase activity, increasing endogenous H₂S levels and further enhancing cellular antioxidant capacity. In summary, DMAE-LA can significantly inhibit cardiomyocyte senescence through multiple antioxidant mechanisms and organelle function protection, providing a potential intervention strategy for targeting cellular senescence in cardiovascular diseases.

The invention discloses an NK cell culture solution and culture and application of NK cells, the NK cell culture solution comprises an activation culture solution and an amplification culture solution, the activation culture solution and the amplification culture solution respectively contain a basal culture medium and respective corresponding cell factors, and the activation culture solution also contains calycosin with the final concentration of 0.1-10 [mu] g / mL and formononetin with the final concentration of 1-20 [mu] g / mL; the amplification culture solution also contains astragaloside IV and soyasaponin I. The components such as calycosin, formononetin, astragaloside IV and soyasaponin I added into the NK cell culture fluid can maintain stable and lasting physiological activity of NK cells and slow down cell senescence, so that secretion of cell factors is promoted, the secretion level of the cell factors is higher, and the purposes of enhancing the persistence of cell activity and improving the killing rate of the NK cells are achieved.

The invention relates to the technical field of biological medicine, in particular to a transcription factor TAF13 related to intervertebral disc nucleus pulposus cell senescence and application of the transcription factor TAF13 in an intervertebral disc degeneration biomarker. The transcription factor TAF13 has specific expression in intervertebral disc degeneration, can be used as a novel molecular marker for disease diagnosis, can also be used as a potential drug action target, can greatly relieve hair growth and development of diseases, and has great significance in diagnosis and treatment of human intervertebral disc degeneration and senescence related diseases.

The invention provides a composition for delaying cell senescence as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading tea polyphenol on a dog bone marrow mesenchymal stem cell exosome, and modifying the surface of the dog bone marrow mesenchymal stem cell exosome with arginine nonamer to prepare a modified tea polyphenol-loaded exosome; the preparation method comprises the following steps of: modifying cholesterol by using arginine nonamer, and preparing lipidosome by using the cholesterol modified by the arginine nonamer, DSPE-PEG2000, phospholipid embedded resveratrol and epigallotein gallate; polysaccharide is extracted from rhizoma polygonati, fructus lycii and ginseng, and rhizoma polygonati / fructus lycii / ginseng polysaccharide is prepared; the preparation method comprises the following steps: mixing an acellular dermal matrix with polygonatum sibiricum / medlar / ginseng polysaccharide, adding lipidosome and a modified tea polyphenol-loaded exosome, co-incubating, and freeze-drying to prepare the composition for delaying cell aging, the composition has a better drug embedding effect, can improve the stability and transdermal absorption effect of the drug, has better antioxidant, antibacterial and anti-inflammatory effects, and can be used for preparing the medicine for delaying cell aging. The effect of delaying skin cell senescence can be better achieved through multiple ways, and safety and degradability are achieved.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

The invention discloses a testis Leydig cell senescence marker and application thereof, the senescence marker is CCN5 protein, the senescence condition of the Leydig cell can be specifically reflected by detecting the CCN5 level of testis tissue, the senescence marker can be used as an index for evaluating Leydig cell senescence and testis senescence, and meanwhile, the senescence marker is an effective supplement for a diagnostic scheme of late onset hypogonadism (LOH). Furthermore, the invention also provides application of a preparation for inhibiting CCN5 protein expression in preparation of a product for improving testis Leydig cell senescence or treating diseases caused by testis Leydig cell senescence, the testis Leydig cell senescence can be improved and the LOH symptom can be treated by reducing CCN5 in a targeted manner, and treatment can be performed aiming at the core phenotypes of'lipid droplet loss' and'fibrosis' of testis Leydig cell senescence. The method is a treatment scheme different from exogenous testosterone supplement, stem cell injection, Senlytics drugs and exosome therapy.